270 related articles for article (PubMed ID: 18718838)
1. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.
Haberstroh A; Schnober EK; Zeisel MB; Carolla P; Barth H; Blum HE; Cosset FL; Koutsoudakis G; Bartenschlager R; Union A; Depla E; Owsianka A; Patel AH; Schuster C; Stoll-Keller F; Doffoël M; Dreux M; Baumert TF
Gastroenterology; 2008 Nov; 135(5):1719-1728.e1. PubMed ID: 18718838
[TBL] [Abstract][Full Text] [Related]
2. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.
Dreux M; Pietschmann T; Granier C; Voisset C; Ricard-Blum S; Mangeot PE; Keck Z; Foung S; Vu-Dac N; Dubuisson J; Bartenschlager R; Lavillette D; Cosset FL
J Biol Chem; 2006 Jul; 281(27):18285-95. PubMed ID: 16675450
[TBL] [Abstract][Full Text] [Related]
3. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
[TBL] [Abstract][Full Text] [Related]
4. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81.
Zeisel MB; Koutsoudakis G; Schnober EK; Haberstroh A; Blum HE; Cosset FL; Wakita T; Jaeck D; Doffoel M; Royer C; Soulier E; Schvoerer E; Schuster C; Stoll-Keller F; Bartenschlager R; Pietschmann T; Barth H; Baumert TF
Hepatology; 2007 Dec; 46(6):1722-31. PubMed ID: 18000990
[TBL] [Abstract][Full Text] [Related]
5. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
[TBL] [Abstract][Full Text] [Related]
6. Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.
Swann RE; Cowton VM; Robinson MW; Cole SJ; Barclay ST; Mills PR; Thomson EC; McLauchlan J; Patel AH
J Virol; 2016 May; 90(9):4530-4543. PubMed ID: 26912610
[TBL] [Abstract][Full Text] [Related]
7. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission.
Brimacombe CL; Grove J; Meredith LW; Hu K; Syder AJ; Flores MV; Timpe JM; Krieger SE; Baumert TF; Tellinghuisen TL; Wong-Staal F; Balfe P; McKeating JA
J Virol; 2011 Jan; 85(1):596-605. PubMed ID: 20962076
[TBL] [Abstract][Full Text] [Related]
9. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
[TBL] [Abstract][Full Text] [Related]
10. Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2.
Vasiliauskaite I; Owsianka A; England P; Khan AG; Cole S; Bankwitz D; Foung SKH; Pietschmann T; Marcotrigiano J; Rey FA; Patel AH; Krey T
mBio; 2017 May; 8(3):. PubMed ID: 28512091
[TBL] [Abstract][Full Text] [Related]
11. [Development of infectious pseudo-particle harboring three subtypes hepatitis C virus glycoproteins and their application in neutralization assays].
Zhang K; Tan WJ; Deng Y; Li J; Wu XB; Ruan L
Bing Du Xue Bao; 2008 Jul; 24(4):287-94. PubMed ID: 18780632
[TBL] [Abstract][Full Text] [Related]
12. Studies on the role of neutralizing antibodies against envelope genes in resolving HCV pseudo-particles infection.
Rafique S; Idrees M; Ali A; Iqbal M
Mol Biol Rep; 2014 Jun; 41(6):3945-50. PubMed ID: 24566682
[TBL] [Abstract][Full Text] [Related]
13. Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors.
Bitzegeio J; Bankwitz D; Hueging K; Haid S; Brohm C; Zeisel MB; Herrmann E; Iken M; Ott M; Baumert TF; Pietschmann T
PLoS Pathog; 2010 Jul; 6(7):e1000978. PubMed ID: 20617177
[TBL] [Abstract][Full Text] [Related]
14. Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions.
Keck ZY; Xia J; Cai Z; Li TK; Owsianka AM; Patel AH; Luo G; Foung SK
J Virol; 2007 Jan; 81(2):1043-7. PubMed ID: 17079294
[TBL] [Abstract][Full Text] [Related]
15. Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry.
Prentoe J; Bukh J
Front Immunol; 2018; 9():2146. PubMed ID: 30319614
[TBL] [Abstract][Full Text] [Related]
16. High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry.
Voisset C; de Beeck AO; Horellou P; Dreux M; Gustot T; Duverlie G; Cosset FL; Vu-Dac N; Dubuisson J
J Gen Virol; 2006 Sep; 87(Pt 9):2577-2581. PubMed ID: 16894196
[TBL] [Abstract][Full Text] [Related]
17. A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission.
Fofana I; Xiao F; Thumann C; Turek M; Zona L; Tawar RG; Grunert F; Thompson J; Zeisel MB; Baumert TF
PLoS One; 2013; 8(5):e64221. PubMed ID: 23704981
[TBL] [Abstract][Full Text] [Related]
18. Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.
Lavie M; Sarrazin S; Montserret R; Descamps V; Baumert TF; Duverlie G; Séron K; Penin F; Dubuisson J
J Virol; 2014 Sep; 88(18):10584-97. PubMed ID: 24990994
[TBL] [Abstract][Full Text] [Related]
19. Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection.
Cowton VM; Angus AGN; Cole SJ; Markopoulou CK; Owsianka A; Dunlop JI; Gardner DE; Krey T; Patel AH
J Virol; 2016 Aug; 90(16):7456-7468. PubMed ID: 27279607
[TBL] [Abstract][Full Text] [Related]
20. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.
Owsianka AM; Tarr AW; Keck ZY; Li TK; Witteveldt J; Adair R; Foung SKH; Ball JK; Patel AH
J Gen Virol; 2008 Mar; 89(Pt 3):653-659. PubMed ID: 18272755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
